fbpx

Treatment Locator

Monoclonal Antibody Therapy

Bebtelovimab

Eli Lilly’s monoclonal antibody Bebtelovimab is authorized for the treatment of mild to moderate coronavirus disease 2019 (COVID-19) in:

  • Adults and pediatric patients (12 years of age and older weighing at least 40 kilograms, which is about 88 pounds) with a positive COVID-19 test, and
  • Individuals who are at high risk for progression to severe COVID-19, including hospitalization or death, and
  • Individuals for whom alternative COVID-19 treatment options approved or authorized by the FDA are not accessible or clinically appropriate.

Bebtelovimab is not authorized for use in the following patient populations:

  • Adults or pediatric patients who are hospitalized due to COVID-19, or
  • Adults or pediatric patients who require oxygen therapy and/or respiratory support due to COVID-19, or
  • Adults or pediatric patients who require an increase in baseline oxygen flow rate and/or respiratory support due to COVID-19 and are on chronic oxygen therapy and/or oxygen support due to underlying non-COVID-19- related comorbidity.

 

 

Preventative Monoclonal Antibody Therapy: EvuSheld

Preventative monoclonal antibody therapy locations are marked with a blue pin on the locator map.

AstraZeneca’s Evusheld is authorized for pre-exposure prophylaxis (prevention) of COVID-19 in certain populations age 12 and older. Specifically, it is for:

  • Individuals who are moderately to severely immunocompromised and may not mount an adequate immune response to COVID-19 vaccines.
  • Individuals with a history of severe adverse reactions to COVID-19 vaccines and/or components of the vaccines.

Eligible individuals should contact their health care provider to find out if this treatment option is appropriate for them.

 

 

Oral Antivirals: Paxlovid and Molnupiravir

Oral antiviral sites are marked with a green pin on the locator map.

Pfizer’s Paxlovid and Merck’s Molnupiravir, are antiviral pills (for oral treatment) authorized for people with mild to moderate COVID-19. These antiviral treatments are available by prescription only and should be initiated as soon as possible after diagnosis of COVID-19, and within five days of symptom onset. Eligible individuals should contact their health care provider to find out if this treatment option is appropriate for them.

To be eligible for Paxlovid you must:

  • Be age 12 or older.
  • Have a positive test result for COVID-19.
  • Be at high risk for severe illness from COVID-19, including hospitalization or death.

Molnupiravir is not recommended for women who are pregnant or breastfeeding. To be eligible for Molnupiravir you must:

  • Be age 18 or older.
  • Have a positive test result for COVID-19.
  • Be at high risk for severe illness from COVID-19, including hospitalization or death.

Resources, guidance, and fact sheets for health care providers as well as patients and caregivers can be found on the U.S. Food and Drug Administration’s emergency use authorization website.

Find a COVID-19 Treatment Location

Location Pin Key
Monoclonal Antibody Therapy Treatments
Preventative Monoclonal Antibody Therapy: EvuSheld
Oral Antivirals: Paxlovid and Molnupiravir
Multiple Treatments Available